Published January 29, 2020 | Version v1
Journal article Open

An Update on Further Progression of NAFLD, NASH with Prospective Therapies Like L-Carnitine (LC), Nicotinamide Ribose (NR) Combination, as well as Apical Sodium Dependent Bile Acids Transporter (ASBT) or Volixibat and Silybin as Alternatives

Creators

  • 1. Scientific Director of Human Reproduction, Punjab, India
  • 2. Scientific Director, Ex-Rotunda-A Centre for Human Reproduction 672,Kalpak Garden, Perry Cross Road, Mumbai, India
  • 3. Consultant Neurologist, Swami Satyanand Hospital, Near NawiKachehri, Baradri, Ladowali Road,Jalandhar, Punjab, India

Description

Introduction

Overweight and obesity in adults and children has escalatedat an astonishing rate in the past few decades bringing in a lot of the cost burden [1]. Increased Adipose Tissue (AT) as well as ectopic fat collection is typical properties of obesity which results in associated comorbidities like, Type 2 Diabetes Mellitus (T2DM), Hypertension, dyslipidemia.Recently Nonalcoholic Fatty Liver Diseases (NAFLD) has become the commonest chronic liver disease correlated with obesity [2]. Right now the therapy of obesity concentrates on lifestyle changes which include exercise.No reduction in obesity incidence has occurred in spite of lifestyle as well as diet changes over the past 3 decades [1]. We have reviewed multiple ways of treating obesity medically that includes Qsymia,Contrave, Thylakoids,GLP-1 agonists ,BAT thermogenesis enhancement utilizing mirabegron, probiotics etc but none have been of help in maintenance of weight reduction for long term other than Bariatric Surgery(BS) [3-9]. Further with escalating obesity liver disorders are increasing remarkably with no effective way of treating them .All over the world work is being done at war footing with the enhanced rates of liver transplants needed inthose under 50 yrs [10,11]. Thus we have further tried to present the advances done in working out some medical therapy to prevent propagation of NAFLD and halt it further to not progress till Nonalcoholic Steato Hepatitis (NASH) level,cirrhosis and Hepatocellular Carcinoma (HCC).

Methods

Thus we did an update on the further advances that are being made in treating NAFLD, NASH and carried out a PubMed search using the MeSH Terms NAFLD; NASH; HCC; Preventive or curative therapies.

Results and Discussion

We came across 377 articles out of which we chose 70 articles for updating the earlier information we had reviewed.No meta-analysis was done.

Notes

International Journal of Clinical and Medical Cases (ISSN:2517-7346)

Files

IJCMC-3-138.pdf

Files (1.4 MB)

Name Size Download all
md5:5ea0371e5af6ef90711cb4388c26630f
1.4 MB Preview Download

Additional details

Related works

Is published in
Journal article: https://www.boffinaccess.com/clinical-and-medical-cases/an-update-on-3-138/IJCMC-3-138.pdf (URL)

References

  • Ng M, FleminT, Robinson M, Thomson B, Graetz N, etal. Global , regional and national prevalenceof overweight and obesity in children and adult during 1980-2013: A Systematicanalysis for the Global Burden of Disease Study 2013. Lancet 2014 Aug;6736:1-16.
  • Younossi ZM. Nonalcoholic fatty liverdisease-A global public health perspective. J Hepatol. 2019 Mar;70(3):531-544.
  • KulvinderKocharKaur, Allahbadia GN, Singh M. An Update onAetiopathogenesis and Management of Obesity. Obesity and Control Therapies: Open Access. 2016;3(1):1-17.
  • KulvinderKocharKaur, Allahbadia GN, Singh M. Hypothalamicinflammation and glioses as aetiopathogenetic factor in high fatdiet induced obesity and varioustherapeutic options to resolve it. Obes Res Open J. 2017; 4(2):44-60.
  • Kaur KK, Allahbadia GN, Singh M. Current advances in pathogenesis in obesity: Role of Hypothaalamicglioses. J ObesWeight Loss. 2018 Jan;3:008:1-11.
  • Kaur KK, Allahbadia GN, Singh M. Have Probiotics and Synbioticspassed the test of time to be implemented in management of obesity and related metabolic disorders-a comprehensive review. AdvObes Weight Manag Control. 2019;9(1):21-28.
  • Kaur KK, Allahbadia GN, Singh M. Weight loss Associated with high protein Intake in Obesity:Interactions of Gut Microbiota in Protein Sources in fluencing this positive effect. Acta Scientific Nutritional Health 2018 June;2(7):80-89.
  • Kaur KK, Allahbadia GN, Singh M. Rosmarinic Acid-A New Hopefor Liver Diseases Like Cirrhosis, Hepatocellular CarcinomaNeeds Translation to Humans. EC Endocrinology and MetabolicResearch. 2019 Aug;289-301.
  • Kaur KK, Allahbadia GN, Singh M. Advances in Targeting the Gut Microbiota for Obesity Therapy. Acta Scientific Microbiology.2019 August;2(9):78-79.
  • Fildes A, Charlton J, Rudisill C, Littlejohns P, Prevost AT, etal. Probability of an obese person attaining normal bodyweight:Cohort study using electronic health records. Am J PublicHealth 2015 Sep;105(9)e54-49.
  • Lee Y, Kwon EY, Choi MS. Dietary isoloquiritigenin at a low doseameliorates insulinresistance and NAFLD in diet induced obesity in C57BL/6J mice. Int J MolSci 2018 Oct;19(10):3281.
  • Schrader M, Costello J, Godinho LF, Islinger M. Peroxisome –mitochondria interplay and disease. J Inherit Metab Dis 2015Jul;38(4):681-702.
  • Wijburg FA, Wust RCI, Visser G, Wanders RJA, Knottnerus SJG,etal. Disorders of mitochondrial long chain fatty acid oxidationand the carnitine shuttle. Rev Endocr Metab Disord. 2018Mar;19(1):93-106.
  • Antonenkov VD, Hiltunen JK. Transfer of metabolitesacross the peroxisomalmembrane. Biochem Biophys Acta.Sep;1822(9):1374-1386.
  • Noland RC, Koves TR, Seiler SE, Lum H, Lust RM, etal. Carnitineinsufficiency caused by aging and overnutrition compromisesmitochondrial performance and metabolic control. J Biol Chem.2009 Aug;284(34):22840-22852.
  • Canto C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, etal.The NAD+ precursorNicotinamideriboside enhances oxidativemetabolism and protects against high fat diet induced obesity.Cell Metab. 2012;6(15):838-847.
  • Garten A, Schuster S, Penke M, Gorski T, De Giorgis T, et al. Physiological and pathophysiologicalroles of NAMPT and NAD metabolism. Nat Rev Endocrinol 2015 Sep;11(9):535-546.
  • Yoshino J, Baur JA, Imai SI. NAD+ Intermediates. The biologyand therapeutic potential of NMN and NR. Cell Metab. 2018Mar;27(3):513-528.
  • Bournat JC, Brown CW. Mitochondrial dysfunction in obesity.CurrOpinEndocrinol DiabetesObes. 2010 Oct;17(5):446-452.
  • Zhong H, Yin H. Role of lipid peroxidation derived 4-hydroxynonenal (4-HNE)in cancer. Focusing on Mitochondria. Redox Biol.2015; 4:193-199.
  • Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, et al. In situdetection of lipid peroxidation and oxidative DNA damage in Nonalcoholic fatty liver diseases. J Hepatol. 2002 Jul;37(1):56-62.
  • Ore A, Akinloye OA. Oxidative stress and Antioxidant Biomarkers in Clinical and Experimental models of Nonalcoholic fatty liver diseases. Medicina. 2019 Jan;55:(2).
  • Salic K, Gart E, Seidel F, Verschuren L, Caspers M, etal. Combined treatment with L-Carnitine and Nicotinamideriboside Improves Hepatic Metabolism and Attenuates Obesity and Liver Steatosis. Int J Mol Sci. 2019 Sep;20(18):4359.
  • Younossi ZM, Anstee QM, Marietti M, Hardy T, Henry L. Global burden of NAFLD and NASH:trends , predictions , risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018Jan;15(1):11-20.
  • Chalassani N, Younossi ZM, Lavine JE, Charlton M, Cusi K,etal. The diagnosis and management ofNonalcoholic fattyliverdiseases:practice guidancefrom the American Associationfor the Studyof Liver Diseases. Hepatol. 2018 Jan;67(1):328-357.
  • Milic S, Lulic D, Stimac D. Nonalcoholic fatty liver diseases :biochemical, metabolic and clinical presentations. World J Gastroenterol. 2014 Jul;20(28):9330-9337.
  • Borodosi L, Marchignoli F, Petroni ML, Marchesin IG. NASH:A glance at the landscape of pharmacological treatment. Ann Hepatol. 2016 Sep-Oct;15(5):673-681.
  • Chalassani N, Younossi ZM, Lavine JE, Diehl AM, Brunt EM, etal. The diagnosis and management of Nonalcoholic fatty liver diseases:practice guidance from the American Association for the Study of Liver Diseases, and the American Gastroenterological Association. Hepatol. 2012 Jun;55(6):2005-2023.
  • EASL-EASO-EASO Clinical Practice Guidelines for the management of Nonalcoholic fatty liver diseases. J Hepatol. 2016Jun;64(6):1388-1402.
  • White DL, Kanwal F, El-SerabHB. Association betweenNonalcoholic fatty liverdiseases and risk for Hepatocellularcancer, based on systematic review. ClinGastroenterolHepatol 2012 Dec;10(12):1342-1359.
  • Mc Pherson S, Hardy T, Henderson E, Burt AD, Day CP, et al. Evidenceof NAFLD progression from steatosisto fibros ingsteatohepatitisusing pairedbiopsies:implications for prognosis and clinicalmanagement. J Hepatol. 2015 May;62(5):1148-1155.
  • Wong VW-S, Wong GL-H, Choi-PC-L, Chan AW-H, Li HY, etal. Disease progression of Nonalcoholic fatty liver diseases: aprospective study of paired liver biopsies at 3 years. Gut.2010;59(7):969-974.
  • Banini B. Nonalcoholic steatohepatitis(NASH) has surpassed hepatitis C as the leading etiology for listing for liver transplant: implications for NASH in children and young adults. American College of Gastroenterology Annual Scientific Meeting 14-19-october 2016;Las Vegas 2016.
  • Hallibasic E, Claudel T, Trauner M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol.2013 Jan;58(1):155-168.
  • Musso G, Gambino R, Cassender M. Cholesterol metabolism and the pathogenesis of Nonalcoholic steatohepatitis. Prog Lipid Res 2013 Jan;58(1):155-168.
  • Mari M, Caballero F, Colell A, Morales A, Caballeria J, etal. Mitochondrial free cholesterol loading sensitizes to TNF and Fasmediated steatohepatitis. Cell Metab. 2006 Sep;4(3):185-188.
  • Siddiqui MS, Fuchs M, Idowu MO, Luketic VA, BoyettS, etal.Severity of Nonalcoholic fatty liver disease and progression totocirrhosis are associatedwith atherogeniclipoprote in profile. ClinGastroenterol Hepatol. 2015 May;13(5):1000-1008.
  • Arquello G, Balboa E, Arresse M, Zanlugo S. Recent in sightson the role of cholesterol in Nonalcoholic fatty liver disease. Biochim Biophys Acta. 2015 Sep;1852(9):1765-1778.
  • Mulder P, Morrison M, Wielinga P, Van Duyvenvoorde W, KoistraT, et al. Surgical removal of inflamed epididymal white adiposetissue attenuates the development of Nonalcoholic steatohepatitisin obesity. Int J Obese(Lond) 2016 Apr;40(4):675-684.
  • Ferslew BX, Xie G, Johnston CK, SuM, Stewart PW, etal. Altered bileacid metabolome in patients with Nonalcoholic steatohepatitis.Dig Dis Sci. 2015 Nov;60(11):3318-3328.
  • Palmer M, Jennings L, Silloerg D, Bliss C, Martin P. et al. A minimally absorbed, oral, apical sodium dependent bile acids transporter(ASBT), increases bile acid excretion, reduces serum lipids, issafe and tolerable in overweight and obese subjects, a population characteristic of NASH. Hepatol. 2016;64(Suppl1):574
  • Perez MJ, Briz O. Bile acid-induced cell injury and protection.World J Gastroenterol. 2009 Apr;15(14):1677-1689.
  • Staels B, Fonseca VA. Bile acid and metabolic regulation:mechanisms and clinical responses to Bile acid sequestration.Diabetes Care. 2009 Nov;32Suppl2:S237-245.
  • Allen K, Jaeschke H, Copple BL. Bile acids induce inflammatorygenes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol. 2011 Jan;178(1):175-186.
  • Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for Nonalcoholic fatty liver disease. Gut. 2017 Jan;66(1):180-190.
  • Siebers N, PalmerM, Silberg DG, Jennings L, Bliss C, et al. Absorption, distribution, Metabolism and excretion of [14C]-Volixibat in healthy men:phase 1 open label study. Eur J DrugMetabPhsarmacokinet. 2018 Feb;43(1):91-101.
  • Hoffmann AF. The enterohepatic circulation of Bile acids inmammals:forms and functions. Front Biosci (Landmark ed). 2009Jan;14:2584-2598.
  • Rao A, Kosters A, Mells JE, Zhang W, Set chellKD, etal. Inhibitionof ileal bile acid uptake protects against Nonalcoholicfatty liver disease in high fat fedmice. Sci Transl Med. 2016Sep;8(357):357ra122.
  • Chiang JYL. Bile acid Metabolism andsignaling in liver disease and therapy. Liver Res 2017 Jun;1(1):3-9.
  • Jelinek DF, Andersson S, Slaughter CA, Russell DW. Cloning and regulation of cholesterol 7 alpha – hydroxylase , the ratelimiting enzymein Bile acid biosynthesis. J Biol Chem 1990May;265(14):8190-8197.
  • Galman C, Arvidsson I, Angelin B, Rudling M. Monitoringhepaticcholesterol 7 alpha –hydroxylaseactivityby assayof the stable bileacid intermediate7α hydroxyl-4 cholesten -3-one in peripheralblood. J Lipid Res. 2003;44(4):859-866.
  • Tiessen RG, Kennedy CA, Keller BT, Levin N, Acevedo L, etal.Safety , tolerabilityand pharmacodynamics of apicalsodium–dependentbile acid transporter inhibition with Volixibat inhealthy adultsand patientswith type 2 diabetes mellitus: arandomized placebo-controlled trial. BMC Gastroenterol. 2018Jan;18(1):3.
  • Salic K, Kleeman R, Wilkins-Port C, McNutty J, Verschuren L, etal. Apical sodium dependentbile acidstransporter inhibitionwith Volixibat improves metabolic aspects and components ofNonalcoholic steatohepatitis in Ldlr-/-Leiden mice. PLoS ONE.2019 June;14(6):e0218459.
  • Bellentani S. The epidemiology of Nonalcoholic fatty liverdiseases. Liver Int. 2017 Jan;37(Suppl1):81-84.
  • Samuel VT, Shulman GI. Nonalcoholic fatty liver disease as anexus of metabolic and hepatic diseases. Cell Metab. 2018 Jan;27(1):22-41.
  • Da Silva HE, Teterina A, Comelli EM, Talbi A, Arendt BM, et al.Nonalcoholic fatty liver disease is associated with dysbiosisindependent of body mass index and insulin resistance. Sci Rep.2018 Jan;8(1):1466.
  • Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hitpathogenesis of Nonalcoholic fatty liver disease (NAFLD). Metab Clin Exp. 2016 Aug;65(8):1038-1048.
  • Fang YL, Chen H, Wang CL, Liang L. Pathogenesis of Nonalcoholicfatty liverdisease(NAFLD). In children and adolescents from ''twohit theory to multiple-hit model. World J Gastroenterol. 2018Jul;24(27):2974-2983.
  • Federicko A, Dallio M, LoguercioC. Silymarin/Silybin and chronicliver disease: a marriage of many molecules. Molecules 2017Jan;22(2):191.
  • Kren V, Walterova D. Silybin and Silymarin-new effects andapplications. Biomed Papers 2005 Jun;149(1):29-41.
  • Vahabzadeh M, Amiri N, Karimi G. Effects of Silymarin on metabolicsyndrome:a review. J Sci Food Agric. 2018 Oct;98(13):4816-4823.
  • Zhang B, XuD, She L, Wang Z, Yang N, et al. Silybin inhibit NLRP3inflassome assembly through the NAD(+)/SIRT pathway inmice with Nonalcoholic fatty liver disease. FASEB J. 2018Feb;32(2):757-767.
  • Ni X, Wang H. Silymarin attenuated hepatic steatosis throughregulation of lipid metabolism and Oxidative stress in a mousemodel of Nonalcoholic fatty liver disease (NAFLD). Am J TranslRes. 2016 Feb;8(2):1073-1081.
  • Liang Q, Wang C, LiB, Zhang AH. Metabolic fingerprinting tounderstand therapeutic effects and mechanisms of Silybinon acute liver damage in rat. Pharmacogn Mag. 2015 JulSep;11(43):586-593.
  • Wang X, Zhang A, Sun H. Power of Metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma. Hepatology.2013;57(5):2072-2077.
  • Zhang A, Sun H, Yan G, Wang P, Han Y, et al. Metabolomics in diagnosis and biomarker discovery of colorectal cancer. Cancer Lett. 2014 Apr:345(1):17-20.
  • Shah VO, Townsend RR, Feldman HL, Pappan KL, Kensicki E, et al. Plasma Metabolomic profilesin different stages of CKD. Clin J AmSocNephrol. 2013 Mar;8(3):363-370.
  • Kaddurah-Daouk R, Weinshiliboum RM, Pharmaco Network. Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin Pharmacol Ther. 2014 Feb;95(2):154-167.
  • Neuman MG, Cohen LB, Neuman RM. Biomarkers in Nonalcoholicfatty liverdiseases. CanJ Gastroenterol Hepatol. 2014Dec;28(11):607-618.
  • Sun R, XuD, Wei Q, Zhang B, Aa J, et al. Silybin ameliorates hepaticlipid accumulation and modulates global metabolism in anNAFLD mouse model. Biomedicine and Pharmacotherapy. 2019Dec;123:109721.